association

Full identifier: http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#association

Assigned to 1 class:

Minted in Nanopublication

 RAVvlWjDH2 comment approve/disapprove edit as derived nanopublication create new with same template

This is the identifier for this whole nanopublication. http://purl.org/np/RAVvlWjDH2... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-14T09:10:10.059+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAVvlWjDH2... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAVvlWjDH2... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAVvlWjDH2... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T07:10:10.059Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
iressa is indicated for the first line treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test see clinical studies 14 limitation of use safety and efficacy of iressa have not been established in patients with metastatic nsclc whose tumors have egfr mutations other than exon 19 deletions or exon 21 l858r substitution mutations see clinical studies 14 iressa is a tyrosine kinase inhibitor indicated for the first line treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test 1 limitation of use safety and efficacy of iressa have not been established in patients whose tumors have egfr mutations other than exon 19 deletions or exon 21 l858r substitution mutations 1
Leoni Bücken
2021-06-14T07:10:10.059Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T07:10:10.059Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T07:10:10.059Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T07:10:10.059Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T07:10:10.059Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T07:10:10.059Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-14T07:10:10.059Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)